The global generalized myasthenia gravis (GMG) management market is poised for substantial growth, with Future Market Insights projecting a compound annual growth rate (CAGR) of 7.6% from 2023 to 2033. According to the latest report, the market, which boasted a valuation of USD 1.32 Billion in 2023, is anticipated to surpass USD 2.96 billion by 2033.
Generalized myasthenia gravis (GMG) is a rare autoimmune disease characterized by skeletal muscle fatigue and weakness, resulting from antibodies that disrupt the interaction between muscles and nerves. With the global aging population, the incidence of this disorder has been steadily increasing over the past decade.
Get your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16488
Recent statistics from the National Library of Medicine indicate that in the USA alone, the incidence of generalized myasthenia gravis (GMG) is 20 per 100,000 people. Notably, there is a higher prevalence among females under 40 years old, while males over 50 years old exhibit a greater propensity. Additionally, childhood MG is more prevalent in Asian nations compared to Western populations, affecting roughly 50% of patients under the age of 15. Reports suggest that the prevalence of this disorder has been on the rise in recent decades, possibly attributed to improved healthcare data collection and the global trend of increasing disease prevalence.
Recognizing the importance of raising awareness and supporting those affected by GMG, numerous organizations, authorities, and sectors are actively engaged in advocacy efforts. The Myasthenia Gravis Foundation of America (MGFA), for instance, is leading initiatives to designate June as Myasthenia Gravis Awareness Month. Through comprehensive publicity campaigns and educational outreach, including the dissemination of a 23-page toolkit, the foundation aims to increase awareness about the condition and available treatment options. Consequently, there has been a notable expansion in the patient population seeking treatment for this ailment.
As the global GMG management market continues to evolve, fueled by advancements in medical research and increasing awareness initiatives, stakeholders across various sectors are poised to play a pivotal role in supporting individuals living with this rare autoimmune disorder.
Key Takeaways:
- On the global level, the disease’s incidence has risen substantially over recent years. This surge is attributed to increased disease awareness and diagnosis rates in both developed and developing nations. The nation’s massively improved reimbursement guidelines concerning the disorder are cruising sales growth.
- On the basis of the study conducted by the National Organization for Rare Disorders (NORD), the condition’s prevalence in the United Kingdom is estimated to be 15 per 100,000 people, a figure that has risen over time. The popularity of novel therapeutic approaches is growing in tandem with the escalating diagnosis speed and favorable reimbursement guidelines for the ailment.
- This is expected to surge the attempts of the industry’s prominent stakeholders in order to establish and obtain approval for novel drugs to treat the illness. The age structure of the population is expected to be another vital factor driving market growth.
- The proportion of people aged 80 and up in the EU population is predicted to more than double between 2021 and 2100, soaring from 6.0% to 14.6%. On the basis of the MDPI Journal of Clinical Medicine, the prevalence of the ailment surges progressively with age. The 60-89-year-old age group has the greatest incidence. As a result, the disease’s prevalence is increasing as the population’s average lifespan rises.
- On the basis of the 2020 epidemiology of myasthenia gravis article posted by Value in Health Journal, the older population comprises of higher incidence of the ailment than younger ages. Furthermore, in the United Kingdom, the pervasiveness of the disorder in the aging population was 46.4 per 100,000, in comparison to 12 per 100,000 in young adulthood.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-16488
Competitive Landscape:
Key players in the global generalized myasthenia gravis (GMG) management market are strengthening the portfolio, pipeline, and treatment emphasis on unique disease treatments.
More Insights into the Generalized Myasthenia Gravis (GMG) Management Market:
The North American market is anticipated to dominate the global GMG management market. In 2020, the North American market was valued at worth USD 0.58 billion. The soaring incidence of the illness and the region’s aging population are the contributing factors to market growth during the forecast period. Furthermore, the region’s established healthcare facilities and favorable reimbursement policies are striving to improve diagnosis and therapy rates in both emerging and advanced economies.
Key Companies Profiled:
- Alexion Pharmaceuticals,
- Argenx,
- UCB Biopharma,
- Horizon Therapeutics,
- Halozyme Therapeutics,
- Hoffmann-La Roche AG,
- Janssen Research & Development, LLC,
- Immunovant Sciences GmbH,
- Sanofi,
- Cartesian Therapeutics
Key Segments Profiled in the Generalized Myasthenia Gravis (GMG) Management Industry Survey:
By Drug Types:
- Monoclonal Antibodies
- FcRn Inhibitors
- Corticosteroid
- Cholinesterase Inhibitors
- Pharmacotherapy
- Therapeutic Plasma Exchange
By End Users:
- Hospitals
- Specialty Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/16488
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
